Absci Corporation has revealed a collaboration with AstraZeneca, a global biopharmaceutical company, aimed at delivering an AI-designed antibody targeting an oncology-specific target. This joint effort leverages Absci's Integrated Drug Creation™ platform alongside AstraZeneca's oncology expertise, with the objective of expediting the discovery of a potential new cancer treatment candidate.
Under the collaboration, Absci will deploy its cutting-edge generative AI technology to develop a therapeutic antibody candidate for the specified oncology target. The agreement encompasses an upfront commitment, R&D funding, milestone payments, and royalties on product sales.
Absci's Integrated Drug Creation™ platform combines generative AI with a suite of scalable wet-lab technologies. The platform generates proprietary data by assessing millions of protein-protein interactions, which are then utilized to train Absci's proprietary AI models. In subsequent iterations, these models validate antibodies designed using de novo AI models. The platform accelerates the drug discovery process, completing the cycle of data collection, AI-driven design, and wet-lab validation within an estimated six weeks. Its aim is to increase the likelihood of successful development outcomes for biologic drug candidates by concurrently optimizing multiple drug attributes and expanding the scope of drug targets, including those traditionally considered "undruggable," such as G protein-coupled receptors (GPCRs) and ion channels.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!